Telix Pharmaceuticals Investor Presentation — August 2024

Document content

Illustration showing TLX250 binding to

carbonic anhydrase IX and internalisation

Credit: UCLA expanded access programDisclaimer

2This presentation should be read in conjunction with our most recent reports and announcements, including our risk factors, lodged with the Australian Securities Exchange (ASX) or on our website .

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction,

including the United States . The information and opinions contained in this presentation aresubject to change without notification .To the maximum extent permitted by law, Telix disclaims any obligation or

undertaking to update or revise any information or opinions contained in this presentation, including any forward -looking statements (as referred to below) contained in this presentation, whether as a result of

new information, future developments, a change in expectations or assumptions, or otherwise . No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the

information contained or opinions expressed in this presentation .

This presentation may contain forward -looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments . Forward - looking statements can

generally be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”